Inlyta 1 mg film-coated tablets

DRUG4 trials

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Assistance Publique Hopitaux De Marseille, Rigshospitalet, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Conditions

Advanced solid tumorCancerEpendymomaGastrointestinal Stromal Tumors (GIST)MedulloblastomaMultiple myelomaNon-Hodgkin lymphomaT-cell prolymphocytic leukemia

Phase 1

MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medulloblastoma and ependymoma

RecruitingCTIS2023-509585-38-00

Assistance Publique Hopitaux De MarseilleEpendymoma, Medulloblastoma

Start: 2024-11-19Target: 40Updated: 2025-11-07

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling

RecruitingCTIS2023-510527-29-00

RigshospitaletCancer

Start: 2020-09-01Target: 600Updated: 2025-04-25

A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST

Active, not recruitingCTIS2024-519176-95-00

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyGastrointestinal Stromal Tumors (GIST)

Start: 2019-05-08Target: 58Updated: 2025-01-13

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01